I agree. This could easily double by the next report. As well as continued improvements in all operations, I am expecting a big positive revaluation of company assets at the next report. After all, dermatology was written down from about $90M in Dec 2022 to $20M in June 23 on the basis of poor returns, given that this operating unit has already delivered over A$13 in direct contribution over the first 4 months I expect this asset to be revalued significantly.
fair price $13.0, page-3
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.16 |
Change
0.055(0.90%) |
Mkt cap ! $530.8M | |||
| Open | High | Low | Value | Volume |
| $6.03 | $6.24 | $5.94 | $1.541M | 255.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 62 | $6.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.16 | 113 | 2 |
View Market Depth
| Last trade - 10.51am 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.12 |
Change
0.055 ( 0.56 %) |
||||
| Open | High | Low | Volume | ||
| $6.01 | $6.24 | $5.97 | 17186 | ||
| Last updated 11.08am 16/05/2024 ? | |||||
| MYX (ASX) Chart |